IO102 is a peptide vaccine containing a 21-mer IDO-derived peptide. IO102 is currently in phase I clinical trial.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A first-in-man study has been performed in 10 melanoma patients where treatment with IO102 was combined with treatment with the checkpoint inhibitor, ipilimumab (anti-CTLA4 antibody). There were no safety concerns as no treatment-related grade 3 or 4 toxicity was reported. Four patients had disease stabilization. At first evaluation, five of the ten treated patients were in stable disease, one of which had an unconfirmed partial response.

An IO102 phase II clinical study is planned to be initiated in Q4 2017.

For detailed data, please go to: Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab